Similar articles for PMID: 25743139

Year	Number of Results
1887	1
2007	1
2010	1
2011	3
2012	5
2013	5
2014	14
2015	26
2016	29
2017	23
2018	14
2019	10
2020	8
2021	7
2022	2
2023	2
2024	0

1

[Effect of tolvaptan on ascites due to malignancy].

Mitsuhashi N, Nemoto S, Satoh Y, Aoki Y, Teranaka R, Sasaki K, Shimazaki R, Ueda A, Nishino H, Akiyama T, Hosokawa I, Yoichi T, Kawamoto J, Kuboki S, Yoshitomi H, Kato A, Shimizu Y, Ohtsuka M, Shimizu H, Miyazaki M. Mitsuhashi N, et al. Gan To Kagaku Ryoho. 2015 Feb;42(2):201-5. Gan To Kagaku Ryoho. 2015. PMID: 25743139 Japanese.

2

Tolvaptan for the treatment of liver cirrhosis oedema.

Sakaida I. Sakaida I. Expert Rev Gastroenterol Hepatol. 2014 Jul;8(5):461-70. doi: 10.1586/17474124.2014.903797. Epub 2014 Mar 29. Expert Rev Gastroenterol Hepatol. 2014. PMID: 24678622 Review.

3

Clinical efficacy of tolvaptan for treatment of refractory ascites in liver cirrhosis patients.

Zhang X, Wang SZ, Zheng JF, Zhao WM, Li P, Fan CL, Li B, Dong PL, Li L, Ding HG. Zhang X, et al. World J Gastroenterol. 2014 Aug 28;20(32):11400-5. doi: 10.3748/wjg.v20.i32.11400. World J Gastroenterol. 2014. PMID: 25170228 Free PMC article.

4

Clinical Factors Predicting the Effect of Tolvaptan for Refractory Ascites in Patients with Decompensated Liver Cirrhosis.

Chishina H, Hagiwara S, Nishida N, Ueshima K, Sakurai T, Ida H, Minami Y, Takita M, Kono M, Minami T, Iwanishi M, Umehara Y, Watanabe T, Komeda Y, Arizumi T, Kudo M. Chishina H, et al. Dig Dis. 2016;34(6):659-664. doi: 10.1159/000448828. Epub 2016 Oct 17. Dig Dis. 2016. PMID: 27750234

5

Prediction of diuretic response to tolvaptan by a simple, readily available spot urine Na/K ratio.

Komiyama Y, Kurosaki M, Nakanishi H, Takahashi Y, Itakura J, Yasui Y, Tamaki N, Takada H, Higuchi M, Gotou T, Kubota Y, Takaura K, Hayashi T, Oh W, Okada M, Enomoto N, Izumi N. Komiyama Y, et al. PLoS One. 2017 Mar 31;12(3):e0174649. doi: 10.1371/journal.pone.0174649. eCollection 2017. PLoS One. 2017. PMID: 28362879 Free PMC article.

6

Re-response to tolvaptan after furosemide dose reduction in a patient with refractory ascites.

Goto A, Terai S, Nakamura M, Matsumoto M, Sakaida I. Goto A, et al. Clin J Gastroenterol. 2015 Feb;8(1):47-51. doi: 10.1007/s12328-014-0545-8. Epub 2014 Dec 5. Clin J Gastroenterol. 2015. PMID: 25475138 Free PMC article.

7

Survival Benefit of Tolvaptan for Refractory Ascites in Patients with Advanced Cirrhosis.

Tajiri K, Tokimitsu Y, Ito H, Atarashi Y, Kawai K, Minemura M, Yasumura S, Takahara T, Shimizu Y, Sugiyama T. Tajiri K, et al. Dig Dis. 2018;36(4):314-321. doi: 10.1159/000489258. Epub 2018 May 31. Dig Dis. 2018. PMID: 29852495

8

Cases with Refractory Ascites and a Delayed Response to Tolvaptan.

Hagiwara S, Nishida N, Chishina H, Ida H, Sakurai T, Komeda Y, Kitano M, Kudo M. Hagiwara S, et al. Intern Med. 2016;55(22):3273-3277. doi: 10.2169/internalmedicine.55.7035. Epub 2016 Nov 15. Intern Med. 2016. PMID: 27853068 Free PMC article.

9

Efficacy of combination therapy with natriuretic and aquaretic drugs in cirrhotic ascites patients: A randomized study.

Uojima H, Hidaka H, Nakayama T, Sung JH, Ichita C, Tokoro S, Masuda S, Sasaki A, Koizumi K, Egashira H, Kako M. Uojima H, et al. World J Gastroenterol. 2017 Dec 7;23(45):8062-8072. doi: 10.3748/wjg.v23.i45.8062. World J Gastroenterol. 2017. PMID: 29259382 Free PMC article. Clinical Trial.

10

Efficacy of tolvaptan for the patients with advanced hepatocellular carcinoma.

Miyazaki M, Yada M, Tanaka K, Senjyu T, Goya T, Motomura K, Kohjima M, Kato M, Masumoto A, Kotoh K. Miyazaki M, et al. World J Gastroenterol. 2017 Aug 7;23(29):5379-5385. doi: 10.3748/wjg.v23.i29.5379. World J Gastroenterol. 2017. PMID: 28839438 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

127 results

Results by year